Single Combination Treatment in **Tinnitus:** versus An 1

International, Multicentre, Parallel-arm, Superiority, 2

Randomised Controlled Trial 3

Stefan Schoisswohl, Ph.D.^{1,2}, Laura Basso, Ph.D.¹, Jorge Simoes, Ph.D.³, Milena Engelke, 4 M.Sc.¹, Berthold Langguth, M.D.¹, Birgit Mazurek, M.D., Ph.D.⁴, Jose Antonio Lopez-5 Escamez, M.D., Ph.D.^{5,6,7,8}, Dimitrios Kikidis, M.D., Ph.D.⁹, Rilana Cima, Ph.D.¹⁰, Alberto 6 Bernal-Robledano, M.Sc. ^{5,6,7}, Benjamin Boecking, Ph.D. ⁴, Jan Bulla, Ph.D. ^{1,11}, Christopher 7 R. Cederroth, Ph.D.^{12, 13}, Holger Crump, Dipl.-Soz.-Wiss.¹⁴, Sam Denys, Ph.D.^{15,16}, Alba 8 Escalera-Balsera, M.Sc. ^{5,6,7}, Alvaro Gallego-Martinez, Ph.D. ^{5,6,7}, Silvano Gallus, Ph.D. ¹⁷, 9 Hazel Goedhart, M.Sc.¹⁸, Leyre Hidalgo-Lopez, M.D.¹⁹, Carlotta M. Jarach, M.Sc.¹⁷, Hafez 10 Kader, M.Sc.²⁰, Michael Koller, Ph.D.²¹, Alessandra Lugo, Ph.D.¹⁷, Steven C. Marcrum, 11 Ph.D.²², Nikos Markatos, B.Sc. (Honors)²³, Juan Martin-Lagos, M.D.^{5,6,24}, Marta Martinez-12 Martinez, M.D., Ph.D.^{5,6,24}, Nicolas Muller-Locatelli, M.D.²⁴, Patrick Neff, Ph.D.^{1,25,26,27}, 13 Uli Niemann, Dr. Ing.²⁰, Patricia Perez-Carpena, M.D., Ph.D.^{5,6,7,28}, Rüdiger Pryss, Ph.D.²⁹, 14 Clara Puga, M.Sc.²⁰, Paula Robles-Bolivar, M.Sc.^{5,6,7}, Matthias Rose, Ph.D.³⁰, Martin 15 Schecklmann, Ph.D.¹, Tabea Schiele, M.Sc.⁴, Miro Schleicher, M.Sc.²⁰, Johannes Schobel, 16 Ph.D.³¹, Myra Spiliopoulou, Dr. habil.²⁰, Sabine Stark, Dipl.-Psych.⁴, Susanne Staudinger, 17 M.A.¹, Alexandra Stege, Ph.D.³², Beat Toedtli, Ph.D.³³, Ilias Trochidis, M.Sc.³⁴, Vishnu 18 Unnikrishnan, M.Sc.²⁰, Evgenia Vassou, M.Sc.²³, Nicolas Verhaert, M.D. Ph.D.^{15,16}, Carsten 19 Vogel, M.Sc.²⁹, Zoi Zachou, M.D.²³ and Winfried Schlee, Ph.D.^{1,33} 20

21

- 23 ² Department of Human Sciences, Institute of Psychology, Universitaet der Bundeswehr München, Neubiberg, 24 Germany
- 25 ³ Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands

26 ⁴ Tinnitus Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,

- 27 Humboldt-Universität zu Berlin, and Berlin Institute of Health
- 28 ⁵ Otology & Neurotology Group CTS495, Department of Genomic Medicine, GENYO. Centre for Genomics
- 29 and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Granada, Spain
- 30 ⁶ Instituto de Investigación Biosanitaria, ibs.GRANADA, Universidad de Granada, Granada, Spain
- 31 ⁷ Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en Enfermedades Raras,
- 32 CIBERER, 28029 Madrid, Spain
- 33 ⁸ Meniere's Disease Neuroscience Research Program, Faculty of Medicine & Health, School of Medical
- 34 Sciences, The Kolling Institute, University of Sydney, Sydney, New South Wales, Australia

²² ¹ Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany

- ⁹ First Department of Otorhinolaryngology, Head and Neck Surgery, National and Kapodistrian University of
- 36 Athens, Hippocrateion General Hospital, Athens, Greece.
- ¹⁰ Department of Health Psychology, Katholieke Universiteit Leuven, Leuven, Belgium.
- 38 ¹¹ Department of Mathematics, University of Bergen, 5020 Bergen, Norway
- ¹² Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
- 40 ¹³ Translational Hearing Research, Tuebingen Hearing Research Center, Department of Otolaryngology, Head
- 41 and Neck Surgery, University of Tuebingen, Tu Dingen, Germany
- 42 ¹⁴ Patient Organisation "Hast Du Toene Leben mit Tinnitus" Bergisch-Gladbach, Bergisch-Gladbach, Germany
- 43 ¹⁵ Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Leuven, Katholieke
- 44 Universiteit Leuven, Leuven, Belgium
- 45 ¹⁶ Department of Neurosciences, Research Group Experimental Otorhinolaryngology (ExpORL), Katholieke
- 46 Universiteit Leuven, Leuven, Belgium
- 47 ¹⁷ Department of Medical Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
- 48 ¹⁸ Tinnitus Hub, London, United Kingdom
- ¹⁹ Department of Mental Health, Hospital Universitario Virgen de las Nieves, Granada, ES, Spain.
- 50 ²⁰ Faculty of Computer Science, Otto-von-Guericke Universitaet Magdeburg, Germany
- 51 ²¹ Center for Clinical Studies, University of Regensburg, Regensburg, Germany
- 52 ²² Ear, Nose, Throat Department, University Hospital Regensburg, Regensburg, Germany
- 53 ²³ First Department of Otorhinolaryngology, Head and Neck Surgery, National and Kapodistrian University of
- 54 Athens, Hippocrateion General Hospital, Athens, Greece.
- ²⁴ Department of Otolaryngology, Hospital Clinico Universitario San Cecilio, Granada, Spain
- ²⁵ Department of Otorhinolaryngology, Head&Neck Surgery, University Hospital Zurich, University of Zurich,
- 57 Switzerland
- 58 ²⁶ Neuro-X Institute, École Polytechnique Fédérale de Lausanne (EPFL), Geneva, Switzerland
- ²⁷ Centre for Cognitive Neuroscience, University of Salzburg, Salzburg, Austria
- 60 ²⁸ Department of Otolaryngology, Hospital Universitario Virgen de las Nieves, Granada, Spain
- 61 ²⁹ Institute of Clinical Epidemiology and Biometry University of Würzburg, Germany
- 62 ³⁰ Department of Internal Medicine and Psychosomatics, Charité Universitätsmedizin Berlin, corporate
- 63 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
- ³¹ Institute DigiHealth, Neu-Ulm University of Applied Sciences, Neu-Ulm, Germany
- 65 ³² Centrale Biobank Charité (ZeBanC), Charité Universitätsmedizin Berlin, corporate member of Freie
- 66 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
- ³³ Institute for Information and Process Management, Eastern Switzerland University of Applied Sciences, St.
- 68 Gallen, Switzerland
- 69 ³⁴ ViLabs, Limassol 3030, Cyprus
- 70

71 Corresponding author:

- 72 Stefan Schoisswohl, Ph.D.
- 73 Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg,
- 74 Germany

75 <u>Stefan.schoisswohl@ukr.de</u>

76 0049 941 941 2096

77 Abstract

78 Tinnitus is associated with a variety of aetiologies, phenotypes, and underlying 79 pathophysiological mechanisms, and available treatments have limited efficacy. A 80 combination of treatments, addressing various aspects of tinnitus, might provide a viable and 81 superior treatment strategy.

82 In this international multicentre, parallel-arm, superiority, randomised controlled trial, patients 83 with chronic subjective tinnitus were recruited from five clinical sites across the EU as part of 84 the interdisciplinary collaborative UNITI project. Patients were randomly assigned using a 85 web-based system, stratified by their hearing and distress level, to single or combination 86 treatment of 12 weeks. Cognitive-behavioural therapy, hearing aids, structured counselling, 87 and sound therapy were administered either alone or as a combination of two treatments 88 resulting in ten treatment arms. The primary outcome was the difference in the change from 89 baseline to week 12 in the total score of the Tinnitus Handicap Inventory (THI) between 90 single and combination treatments in the intention-to-treat population. All statistical analysis 91 were performed blinded to treatment allocation.

92 674 patients of both sexes aged between 18 and 80 years were screened for eligibility. 461 93 participants (190 females) with chronic subjective tinnitus and at least mild tinnitus handicap 94 were enrolled, 230 of which were randomly assigned to single and 231 to combination 95 treatment. Least-squares mean changes from baseline to week 12 were -11.7 for single 96 treatment (95% confidence interval [CI], -14.4 to -9.0) and -14.9 for combination treatments 97 (95% CI, -17.7 to -12.1), with a statistically significant group difference (p=0.034). 98 Cognitive-behavioural therapy and hearing aids alone had large effect sizes, which could not 99 be further increased by combination treatment. No serious adverse events occurred.

In this trial involving patients with chronic tinnitus, all treatment arms showed improvement in THI scores from baseline to week 12. Combination treatments showed a stronger clinical effect than single treatment, however, no clear synergistic effect was observed when combining treatments. We observed rather a compensatory effect, where a more effective treatment offsets the clinical effects of a less effective treatment.

105 ClinicalTrials.gov Identifier: NCT04663828.

106

108 **Main**

Tinnitus is defined as "the conscious awareness of a tonal or composite noise for which there is no identifiable external acoustic source",¹ with an estimated prevalence of 14.4% (95% confidence interval [CI], 12.6 to 16.5) in the global population, with 2.3% (95% CI, 1.7 to 3.1) being severely affected.² Severe tinnitus is associated with emotional stress, cognitive dysfunction, and/or autonomic arousal, leading to maladaptive behavioural changes and functional disability.¹

Numerous causes and risk factors for tinnitus have been identified,³ whereby peripheral and 115 116 central mechanisms are involved in its emergence and maintenance, exemplified by pathological alterations in the ear, along the auditory pathway⁴, as well as in non-auditory 117 brain regions.⁵ There is a broad spectrum of aetiologies, phenotypes, and underlying 118 119 pathophysiological mechanisms of tinnitus. Many adults with chronic tinnitus report having 120 tried multiple tinnitus treatments before finding a treatment that reduces their tinnitus distress.⁶ Despite the availability of treatment guidelines,^{7,8} clear guidance on which treatment 121 122 strategy is best for the individual patient is not yet available. A viable option for clinical 123 management could be the combination of different treatment options to target various facets 124 of this symptom simultaneously.

However, studies on the efficacy of combining clinical interventions are scarce.^{9–11} A prominent example of combining different treatment types is represented by the combination of a specific acoustic therapy with directive counselling termed Tinnitus Retraining Therapy.¹²

The primary objective of the current trial was to compare the effect of single against combination treatments for patients with chronic tinnitus. Four established treatment strategies were selected: cognitive-behavioural therapy (CBT), hearing aids (HA), structured counselling (SC), and sound therapy (ST).¹³ Participants were randomised either to a single treatment out of this set of treatments or to a combination of two treatments. Further, we

attempt to overcome methodological weaknesses¹⁴ of previous trials by investigating a large
multinational sample of tinnitus patients, using harmonised patient selection and screening
procedures, as well as standardised interventions and assessments.

137

138 Methods

139 Study design

140 This was an investigator-initiated, international, multicentre, parallel-arm, superiority, 141 randomised controlled clinical trial conducted in five hospitals across four European countries 142 (Belgium, Germany, Greece, and Spain; see **Table S1** in the Supplementary Appendix) as 143 part of the UNITI project (Unification of Treatments and Interventions for Tinnitus Patients).¹⁵ Included patients received treatment between April 2021 and December 2022. 144 145 Detailed information about the trial rationale, design, methodological approaches, and 146 statistical analysis strategies are published in the study protocol and statistical analysis plan 147 (SAP).^{16,17} The study was approved by local ethics committees at every clinical site 148 independently. Further, all authors vouch for the completeness and correctness of the data, adherence of the trial to the study protocol,¹⁶ as well as adherence of data analysis strategies 149 to the SAP.¹⁷ A detailed list of author contributions can be found in the Supplementary 150 151 Appendix. Written informed consent was obtained from all eligible patients prior to trial 152 participation. For the preparation of this report we used the CONSORT guidelines (Consolidated Standards of Reporting Trials).¹⁸ 153

154

155 **Participants**

Adults of both sexes (self-reported) aged between 18 and 80 years with chronic subjective tinnitus (lasting for six months or more) were recruited and screened at each clinical site. Inclusion criteria for trial participation were at least mild tinnitus handicap according to the Tinnitus Handicap Inventory¹⁹ (THI; score \geq 18) and tinnitus as primary complaint. Exclusion

160 criteria were: presence of a mild cognitive impairment according to the Montreal Cognitive 161 Assessment²⁰ (MoCa; score ≤ 22); any relevant ear disorders or acute infections of the ear; 162 one deaf ear; severe hearing loss (inability to communicate properly) as well as serious 163 internal, neurological, or psychiatric conditions. Existing drug therapies with psychoactive 164 substances had to be stable, and no start of any other tinnitus-related treatment in the last three 165 months before trial participation was allowed. A detailed list of all eligibility criteria can be 166 found in the trial protocol.¹⁶ Written informed consent was obtained from all participants.

167

168 Randomisation and blinding

169 After successful on-site screening, eligible participants were stratified in four equally sized 170 strata based on their THI total score (low [< 48] and high [≥ 48] tinnitus-related handicap) and 171 hearing aid indication (ves and no, criteria for hearing aid indication: **Table S2**). Participants 172 were then randomised to one of ten treatment arms comprised of single (CBT, HA, SC, ST) 173 and combination interventions (CBT+HA, CBT+SC, CBT+ST, HA+SC, HA+ST, SC+ST). 174 Patients from the two strata without hearing aid indication were not randomised in treatment 175 groups that comprised HA treatment. Randomisation was conducted at each clinical site with 176 an interactive web response system developed together with biostatisticians from the contract 177 research organization Excelya (www.excelya.com). Excelya was further responsible to 178 monitor all randomisation proceedings. Treatment codes were used to assure blindness of the 179 statistical analysis team to the type of treatment patients received. Unblinding was conducted 180 after analyses completion. See study protocol and statistical analysis plan for more detailed information.^{16,17} 181

182

183 **Procedures**

184 Single and combination treatments were applied over a 12-week treatment phase. CBT was 185 based on the concept of fear-avoidance using exposure therapy²¹ and delivered by trained

186 psychologists or psychotherapists in weekly face-to-face group sessions (1.5-2 hours; group 187 size: six to eight participants). For HA treatment, behind-the-ear hearing instruments (Type 188 Signia Pure 312 7X; Sivantos Pte. Ltd., Singapore, Republic of Singapore/ WSAudiology, 189 Lynge, Denmark) were fitted bilaterally with all noise-related signal processing deactivated 190 by audiologists or HA acousticians according to the National Acoustic Laboratories-Non-Linear 2 generic amplification proceeding.²² SC and ST were self-administered on a daily 191 basis via dedicated mobile applications.²³ SC consisted of 12 chapters featuring structured 192 193 patient education and tips on how to handle tinnitus distress. ST included a set of various 194 artificial and naturalistic sounds. All treatment procedures were designed by dedicated experts in their respective fields (see **Table S3**) and described in detail in the study protocol.¹⁶ 195 196 Demographic and clinical characteristics were assessed at baseline (before treatment) using 197 the European School of Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-

198 SQ).²⁴ Outcome measures were assessed at baseline, interim (after 6 weeks of treatment),

final (after 12-week treatment period), and follow-up (36 weeks after baseline) visits. An
additional follow-up visit (48 weeks after baseline) was conducted on a voluntary basis. Due

201 to its voluntary nature and the associated large amount of missing data, this additional follow-

202 up was not included in the final outcome measure analysis.

203

204 **Outcome measures**

The primary outcome was the difference in change from baseline to final visit (after 12 weeks of treatment) in the Tinnitus Handicap Inventory (THI),¹⁹ which consists of 25 items to quantify tinnitus handicap (total scores range: 0-100), between single and combination treatment. Changes from baseline to interim visit, and follow-up were examined in secondary analyses as well. Secondary outcome measures included the Tinnitus Functional Index (TFI),²⁵ the Mini Tinnitus Questionnaire (Mini-TQ),²⁶ the Patient Health Questionnaire for Depression (PHQ-D/PHQ-9),²⁷ the abbreviated version of the World Health Organisation -

Quality of Life questionnaire (WHO-QoL)²⁸ as well as numeric rating scales (NRS) for
tinnitus impairment, tinnitus loudness, tinnitus-related discomfort, annoyance, unpleasantness,
and ability to ignore the tinnitus.²⁹ Clinical improvement was measured with the Clinical
Global Impression Scale – Improvement (CGI-I).³⁰
Adverse (AE) and serious adverse events (SAE) were defined according to the guidelines for

Good Clinical Practice §3 (6,8). AEs were assessed and recorded during each visit with respect to start and end date, intensity, relation to intervention, impact on treatment, and actions taken. Any SAE during the 12-week treatment phase led to a stop of the patient's respective treatment and was immediately reported to the local ethics committee.

221

222 Statistical Analysis

The sample size was determined a priori on an estimated effect size of 0.26, an alpha level of 5% and a power of 80% (two-sided test). Based on that, the necessary sample size is 468.

225 Considering potential dropouts, the aim was to recruit a total sample size of N = 500.¹⁶

The statistical analysis was performed in the intention-to-treat (ITT) population of N = 461, including all randomised participants, regardless of compliance with the study protocol. For the primary analysis (combination against single treatments), we estimated that with a twotailed alpha level of less than 0.05, the sample size of N = 461 provides the trial with 90% power to detect an effect size of 0.30 (lower end of 95% CI for effect size of behavioural therapy interventions according to the latest Cochrane Review on tinnitus).³¹

For the ITT analysis, missing values (THI: 18%, education: 3.5%, PHQ-9 baseline: 2.6%) were imputed using multilevel imputation (R package mitml)^{32,33}; see **Figure S2** for the distribution of imputed THI values. The missing at random assumption was checked as described in the SAP and no indications of violation were found. As sensitivity analysis, a per-protocol analysis was conducted on all patients who met the requirements for treatment

compliance as defined in the SAP (N = 185, **Table S32**).³⁴ An additional sensitivity analyses was performed without imputation of the primary outcome (**Table S34**).

239 The analysis of the primary objective was performed in the ITT population to test the efficacy 240 of combination treatments against single treatments. Further comparisons between single 241 versus combination treatments for all 4 single treatments separately (CBT single vs. 242 combined, HA single vs. combined, SC single vs. combined, ST single vs. combined) as well as comparisons between all ten treatment arms were performed.^{16,34} To address all objectives, 243 mixed effect models were applied (with REML using the lme4 R package)³⁵ by considering 244 245 the outcome as the response variable and including the corresponding objective, time point 246 (baseline, interim visit, final visit, and follow-up), and objective-by-time interaction as fixed 247 effects, including centre and subject ID as random intercepts. The models were adjusted for 248 the following covariates: age, sex, educational attainment, hearing aid indication, and PHQ-9 249 baseline scores.³⁴ The results of the remaining objectives as described in the SAP are reported

250 in the Supplementary Appendix.

251 Results are reported as least-squares mean changes (obtained via the emmeans R package)³⁶

with 95% confidence intervals. All analyses were performed in R (version 4.2.2).

De-identified data (pseudo-anonymised code) were gathered in a central database, which was regularly monitored and systematically checked for missing and invalid data (every six weeks). After database closure and prior to analysis, data from each clinical centre were checked again for validity and completeness. This study was registered at ClinicalTrials.gov, NCT04663828.



259

260 Figure 1. Trial Profile

A total of 674 patients were screened, of whom 461 met the trial inclusion criteria and were randomly assigned to one of ten treatment arms comprised of a single treatment or a combination of two treatments out of four

different therapy approaches - cognitive-behavioural therapy (CBT), hearing aids (HA), structured counselling

264 (SC), and sound therapy (ST). 230 (49.9%) were assigned to single treatments (CBT, HA, SC, or ST) and 231

265 (50.1%) were assigned to combination treatments (CBT+HA, CBT+SC, CBT+ST, HA+SC, HA+ST, SC+ST).

266 Patients without hearing aid indication were only randomised to treatments without HA. An extended version of

the patient's flowchart can be found in **Figure S1**. Quantity and reasons for trial exclusion during eligibility

assessments and trial discontinuation can be seen from **Tables S5 – S9**.

269 **Results**

Between Apr 16, 2021, and Sept 20, 2022, 674 persons with tinnitus were assessed for 270 271 eligibility, of whom 461 (68.3%) fulfilled the inclusion criteria and consented to participate. 272 After randomisation, 230 were allocated to single treatments and 231 were allocated to 273 combination treatments (Figure 1). The initial planned sample size for the trial was 500 patients.¹⁶ Since our study plan required a recruitment of an exact number of patients with 274 275 specific tinnitus profiles (eligibility criteria and stratification proceedings), plus the trial was 276 performed during the COVID-19 pandemic, recruitment and inclusion processes took us 277 significantly longer than expected. Hence, we closed the trial in December 2022 with N = 461278 included and treated patients, in order to keep to the schedule of our funding period. A post 279 hoc power computation indicates that with a two-tailed alpha level of less than 5%, the 280 available sample size of N = 461 provides our trial with 79.5% power to detect an effect size 281 of 0.26.

282 Table 1 shows the baseline characteristics by treatment arm. Mean baseline THI total scores 283 were 48.5 (SD 19.5) in the single treatment group and 47.4 (SD 19.9) in the combined 284 treatment group. Except for age and hearing aid indication, the baseline characteristics were 285 generally well balanced between the treatment arms (see **Table 1** and **Table S10**). Both age 286 and hearing aid indication were considered as covariates during statistical analyses. The 287 difference in hearing aid indication results from randomising only individuals with relevant 288 hearing loss to HA treatment arms. Results of audiometric measurements are shown in Figure 289 S3 and S4. Participants' baseline characteristics were similar to the group of persons with 290 tinnitus seeking medical help in the general population (Table S4).

Table 1. Demographic and clinical characteristics of the participants at baseline (stratified by treatment arm).												
Characteristics		CBT (n=56)	HA (n=59)	SC (n=56)	ST (n=59)	CBT+HA (n=17)	CBT+SC (n=51)	CBT+ST (n=54)	HA+SC (n=19)	HA+ST (n=27)	SC+ST (n=63)	Overall (N=461)
Der	mographic char	acteristics	(1 0))	(1 0 0)	(11 0))	((1 01)		(((11 00)	(1(102)
Sex												
	Male (%)	34	36	39	32	12	27	33	12	18	28	271
		(60.7%)	(61.0%)	(69.6%)	(54.2%)	(70.6%)	(52.9%)	(61.1%)	(63.2%)	(66.7%)	(44.4%)	(58.8%)
	Female (%)	22	23	17	27	5	24	21	7	9	35	190
		(39.3%)	(39.0%)	(30.4%)	(45.8%)	(29.4%)	(47.1%)	(38.9%)	(36.8%)	(33.3%)	(55.6%)	(41.2%)
Age (years)		48.8	53.4	49.8	50.3	56.0	54.0	46.4	51.6	55.0	51.2	51.1
		±12.3	±11.7	±13.1	±14.0	±10.4	±12.0	±12.9	± 14.0	±11.2	±9.8	±12.4
PHQ-9 total score		7.3	7.3	7.2	8.5	5.8	6.8	7.9	6.8	7.0	7.0	7.3
		±4.9	±4.8	±4.5	±5.2	±4.6	±4.3	±5.0	±3.2	±5.6	±5.5	±4.9
Tinnitus characteristics												
Tinnitus duration		119	126	85	115	101	154	110	159	124	119	119
(in months)		±127	±100	±77	±114	±111	±140	±99	±144	±108	±116	±113
Hearing aid		19	59	19	20	17	18	17	19	27	19	234
indication (%)		(33.9%)	(100%)	(33.9%)	(33.9%)	(100%)	(35.3%)	(31.5%)	(100%)	(100%)	(30.2%)	(50.8%)
THI total score		47.8	48.8	48.6	48.7	42.2	45.5	48.0	52.2	50.1	47.2	48.0
		± 20.3	±19.2	±20.6	± 18.1	± 18.9	± 18.9	±19.3	±21.9	± 20.1	±20.9	±19.7
TFI total score		47.8	50.6	48.5	50.9	46.1	42.9	47.4	51.7	54.5	48.1	48.6
		±21.4	± 18.8	±20.7	±18.1	±18.9	±18.8	±22.7	±21.3	±21.4	±20.9	±20.3
Mini-TQ total		11.4	12.2	11.8	12.5	10.7	11.2	12.3	11.9	12.3	12.0	11.9
score		±5.2	±4.6	±5.4	±5.0	±4.0	±5.0	±4.6	±5.2	±6.0	±5.2	±5.0
Tin	nitus loudness	6.2	6.7	6.4	6.3	6.3	6.0	6.2	6.4	7.2	6.3	6.4
(rating)		± 2.1	±1.7	±2.4	±2.1	±2.7	±2.6	±2.6	±2.3	±1.6	±2.2	±2.2

291 Table 1. Demographic and Clinical Characteristics of the Participants at Baseline.

- 292 Data are n (%) or mean \pm SD.
- 293 PHQ-9 scores range from 0 to 27, with higher scores indicating greater severity of depression.
- 294 The definition for hearing aid indication is given in Table S2.
- 295 THI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus.
- 296 TFI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus.
- 297 Mini-TQ scores range from 0 to 24, with higher scores indicating greater severity of tinnitus.
- 298 Tinnitus loudness (rating) scores range from 0 to 10, with higher scores indicating greater loudness of tinnitus.
- Abbreviations: CBT = Cognitive-Behavioural Therapy; HA = Hearing Aids; PHQ-9 = Patient Health
- 300 Questionnaire for Depression; SC = Structured Counselling; ST = Sound Therapy; TFI = Tinnitus Functional
- 301 Index; THI = Tinnitus Handicap Inventory; TQ = Tinnitus Questionnaire.
- 302
- 303 Regarding the primary objective, the least-squares mean change from baseline to week 12 in
- the THI total score was -11.7 (95% confidence interval [CI], -14.4 to -9.0) for the single
- 305 treatment groups and -14.9 (95% CI, -17.7 to -12.1) for the combination treatment arms (see

306 Figure 2 & Table 2) (interaction effect [single vs. combination treatments at final visit vs.

- baseline] $\beta = 3.2, 95\%$ CI, 0.2 to 6.1, p = 0.034). Model parameters and model assumptions
- 308 for the primary objective can be found in **Table S12** and **Figure S5**. The least-squares mean

309 change from baseline to week 12 in the THI total score for the single vs. combination

310 treatment comparison for each treatment strategy is reported in **Table 2**, and separately for

311 every treatment arm in **Table 3** and **Figure S6**; and further separated by hearing aid indication

312 in **Table S13** and tinnitus severity in **Table S14**. Figure 2 shows least-squares mean changes

from baseline to interim visit at week 6, final visit at week 12, and follow-up at week 36 for

both the overall and individual single-combination treatment comparison. The results of the

- remaining objectives (as outlined in the SAP)¹⁷ and time points (interim visit and follow up)
- 316 are reported in **Tables S16 S18**.

Regarding the secondary outcome measures, least-squares mean change from baseline to week 12 for TFI, Mini-TQ, PHQ-9, WHO-QoL, and NRS (all objectives) are shown in **Tables 2** and **3** as well as **Tables S19 – S31**. Results of CGI-I are reported descriptively for

320 single and combination treatment groups at final visit, see **Figure S7 & S8**, and separated by

321 hearing aid indication (Figure S9) and tinnitus severity (Figure S10).

No serious adverse event was evident in any participant. Adverse events appeared in 49 (21.3%) participants in single treatment groups, and in 49 (21.2%) participants in combination treatment groups. A full listing of all adverse events is provided in **Table S11**. Information on treatment adherence is given in **Figure S1**

325 treatment adherence is given in **Figure S1**.

326 Pairwise post-hoc contrasts for the THI least-squares mean change revealed statistically

327 significant (Bonferroni adjusted) differences between ST and CBT, ST and CBT+SC, ST and

328 CBT+ST, ST and HA, and ST and HA+SC. For all other treatment contrasts, no statistically

329 significant differences were found (all p-values > 0.050). Statistical parameters for all post-

330 hoc contrasts are listed in **Table S15.** The intention-to-treat and the sensitivity analysis

331 yielded similar results (**Table S34**). Per-protocol findings were different for the overall single

332 vs. combination contrast (no statistical superiority of combination treatment; $\beta = 2.8$, 95% CI,

-1.6 to 7.2, p = 0.206) (Figure S11, Tables S32 – S33). Exploratory analysis included the

334 effect size estimates Cohen's d for all treatment arms which are shown in Table 3 and Figure

335336

2.





338 Figure 2. Least-Squares Mean Changes from Baseline to interim visit (6w), final visit (12w) and follow-up

339 (36w) in THI total score. A) single and combination treatments; C) CBT+HA; D) CBT+SC; E) CBT+ST; F)

HA+SC; G) HA+ST; H) SC+ST; and B) Cohen's d values for all treatment arms (change in THI total score from
baseline to final visit). Total THI scores range from 0 to 100, with higher scores indicating greater severity of

- baseline to final visit). Total THI scores range from 0 to 100, with higher scores indicating greater severity of tinnitus, Error bars represent 95% confidence intervals, Abbreviations: CBT = Cognitive-Behavioural Therapy:
- 342 tinnitus. Error bars represent 95% confidence intervals. Abbreviations: CBT = Cognitive-Behavioural Therapy;
- 343 HA = Hearing Aids; SC = Structured Counselling; ST = Sound Therapy; THI = Tinnitus Handicap Inventory.
- 344

Table 2. Primary and Secondary Clinical Outcomes at Final Visit: Single vs. Combination (Intention-to-Treat Population).										
	All treatments		Cognitive Behavioural Therapy		Hearing Aid		Structured Counselling		Sound Therapy	
	Single	Combination	Single	Combination	Single	Combination	Single	Combination	Single	Combination
Primary outcome										
THI										
Change from baseline	-11.7	-14.9	-16.9	-15.6	-14.4	-15.7	-12.0	-15.5	-3.8	-13.2
(95% CI)	(-14.4 to -9.0)	(-17.7 to -12.1)	(-22.8 to -10.9)	(-19.5 to -11.7)	(-19.5 to -9.4)	(-20.7 to -10.7)	(-17.5 to -6.5)	(-19.3 to -11.7)	(-9.3 to 1.6)	(-16.7 to -9.8)
Secondary Outcome										
TFI										
Change from baseline	-11.0	-11.6	-16.1	-12.1	-14.5	-13.9	-9.7	-10.1	-3.7	-11.7
(95% CI)	(-13.9 to	(-14.7 to	(-22.1 to	(-16.3 to	(-20.2 to	(-19.4 to	(-15.5 to	(-14.0 to	(-9.6 to	(-15.5 to
	-8.0)	-8.5)	-10.1)	-7.9)	-8.9)	-8.4)	-3.9)	-6.2)	2.1)	-7.9)
Mini-TQ										
Change from baseline	-2.9	-3.4	-4.1	-3.8	-3.5	-3.0	-2.9	-3.4	-1.2	-3.0
(95% CI)	(-3.6 to -2.2)	(-4.1 to -2.7)	(-5.5 to -2.6)	(-4.8 to -2.8)	(-4.7 to -2.4)	(-4.2 to -1.9)	(-4.3 to -1.4)	(-4.3 to -2.5)	(-2.6 to 0.2)	(-3.9 to -2.2)
NRS-2										
Change from baseline	-0.8	-0.8	-0.5	-0.8	-1.4	-0.8	-0.8	-0.7	-0.3	-0.8
(95% CI)	(-1.2 to -0.4)	(-1.2 to -0.4)	(-1.4 to 0.3)	(-1.4 to -0.2)	(-2.2 to -0.6)	(-1.6 to -0.1)	(-1.6 to 0.0)	(-1.2 to -0.2)	(-1.0 to 0.5)	(-1.3 to -0.3)
PHQ-9										
Change from baseline	-1.7	-1.4	-1.7	-1.7	-2.3	-1.5	-1.7	-1.3	-0.8	-1.3
(95% CI)	(-2.3 to	(-2.1 to	(-3.0 to	(-2.6 to	(-3.5 to	(-2.6 to	(-3.1 to	(-2.2 to	(-2.2 to	(-2.2 to
	-1.0)	-0.8)	-0.3)	-0.8)	-1.2)	-0.4)	-0.4)	-0.5)	0.6)	-0.4)

Table 2. Primary and Secondary Clinical Outcomes at Final Visit: Single vs. Combination (ITT). 345

346 Values depict least-squares mean changes at week 12 for primary and secondary outcomes with 95% confidence intervals.
 Table 3. Primary and Secondary Clinical Outcomes at Final Visit: All Treatment Arms (Intention-to-Treat Population).

- 347 Higher total scores on the THI, TFI and Mini-TQ indicate greater severity of tinnitus.
- 348 Higher total scores on the NRS-2 indicate greater loudness of tinnitus.
- 349 Higher total scores on the PHQ-9 indicate greater severity of depression.
- 350 Further objectives and secondary clinical outcomes not reported in this table can be seen in the Supplementary Appendix.
- 351 Abbreviations: NRS = Numeric Rating Scale; PHQ-9 = Patient Health Questionnaire for Depression; TFI = Tinnitus Functional Index; THI = Tinnitus Handicap Inventory; TQ =
- 352 Tinnitus Questionnaire.
- 353
- 354

	СВТ	HA	SC	ST	CBT+HA	CBT+SC	CBT+ST	HA+SC	HA+ST	SC+ST
Primary outcome										
THI										
Change from baseline	-16.9	-14.4	-12.0	-3.8	-15.2	-17.4	-14.1	-20.0	-12.9	-12.7
(95% CI)	(-22.7 to -11.0)	(-19.7 to -9.2)	(-17.5 to -6.5)	(-9.2 to 1.5)	(-26.0 to -4.4)	(-23.8 to -11.0)	(-19.8 to -8.4)	(-29.3 to -10.8)	(-20.5 to -5.3)	(-17.8 to -7.5)
Cohen's d	0.93	1.00	0.83	0.24	1.13	1.19	0.80	1.35	0.78	0.71
(95% CI)	(0.70 to 1.21)	(0.78 to 1.28)	(0.51 to 1.27)	(-0.02 to 0.53)	(0.74 to 1.83)	(0.91 to 1.59)	(0.55 to 1.12)	(0.98 to 1.99)	(0.43 to 1.37)	(0.46 to 1.02)
Secondary Outcome										
TFI										
Change from baseline	-16.1	-14.5	-9.7	-3.7	-15.1	-10.9	-12.2	-10.1	-15.8	-9.4
(95% CI)	(-22.2 to -10.0)	(-20.1 to -8.9)	(-15.6 to -3.8)	(-9.5 to 2.0)	(-26.1 to -4.0)	(-17.4 to -4.4)	(-18.5 to -5.9)	(-20.0 to -0.2)	(-24.0 to -7.6)	(-15.1 to -3.8)
Mini-TQ	,	,	,	,	,		,	,		,
Change from baseline	-4.1	-3.5	-2.9	-1.2	-4.0	-4.1	-3.6	-3.2	-2.3	-2.9
(95% CI)	(-5.5 to -2.6)	(-4.8 to -2.2)	(-4.3 to -1.4)	(-2.6 to 0.2)	(-6.7 to -1.3)	(-5.6 to -2.6)	(-5.0 to -2.2)	(-5.5 to -0.9)	(-4.3 to -0.4)	(-4.2 to -1.6)
NRS-2										
Change from baseline	-0.5	-1.4	-0.8	-0.3	-1.0	-0.9	-0.7	-0.3	-1.1	-0.7
(95% CI)	(-1.4 to 0.3)	(-2.1 to -0.6)	(-1.6 to 0.0)	(-1.1 to 0.5)	(-2.5 to 0.6)	(-1.8 to 0.0)	(-1.5 to 0.1)	(-1.6 to 1.1)	(-2.2 to -0.1)	(-1.5 to 0.0)
PHQ-9										
Change from baseline	-1.7	-2.3	-1.7	-0.9	-1.2	-1.8	-1.8	-2.0	-1.3	-0.8
(95% CI)	(-3.0 to -0.3)	(-3.6 to -1.1)	(-3.1 to -0.4)	(-2.2 to 0.4)	(-3.7 to 1.2)	(-3.2 to -0.3)	(-3.2 to -0.4)	(-4.2 to 0.2)	(-3.1 to 0.6)	(-2.1 to 0.4)

355

Table 3. Primary and Secondary Clinical Outcomes at Final Visit: All treatment Arms (ITT).

356 Values depict least-squares mean changes at week 12 for primary and secondary outcomes with 95% confidence intervals.

357 Higher total scores on the THI, TFI and Mini-TQ indicate greater severity of tinnitus.

358 Higher total scores on the NRS-2 indicate greater loudness of tinnitus.

359 Higher total scores on the PHQ-9 indicate greater severity of depression.

- 360 Cohens d indicate the standardised effect size of the respective treatment.
- 361 The effect sizes and the corresponding confidence intervals were first computed in each of the 50 imputed data sets before they were averaged to a single value.
- 362 Further objectives and secondary clinical outcomes not reported in this table can be seen in the Supplementary Appendix.
- 363 Abbreviations: CBT = Cognitive-Behavioural Therapy; HA = Hearing Aids; NRS = Numeric Rating Scale; PHQ-9 = Patient Health Questionnaire for Depression; SC =
- 364 Structured Counselling; ST = Sound Therapy; TFI = Tinnitus Functional Index; THI = Tinnitus Handicap Inventory; TQ = Tinnitus Questionnaire.
- 365

366 **Discussion**

367 In this randomised trial on chronic tinnitus, the efficacy of established tinnitus treatments 368 (CBT, HA, SC, and ST) applied either alone or as a combination of two treatments was 369 investigated. All treatments were safe and the improvement in THI scores from baseline to 370 week 12 was statistically stronger for combination compared to single treatment. However, a 371 more detailed analysis of our data by pairwise post hoc comparisons of the various treatment 372 arms suggests that the additional effect of a treatment combination depends on the efficacy of 373 a single treatment. In the case of ST, a clear superiority in favour of combination treatment 374 was present, with the combination CBT+ST being statistically more effective than single ST. 375 Importantly, there was no statistically significant difference between CBT alone and 376 CBT+ST. This finding shows that combining a treatment with low efficacy (in this case ST) 377 together with a treatment of high efficacy (in this case CBT) does not lead to a simple 378 regression to the mean.

379 Rather the high-efficacy treatment counterbalances the effect of the low-efficacy treatment 380 and elevates the clinical improvement up to a level comparable to the single high-efficacy 381 treatment. Together with the observation that ST was the treatment which demonstrated the 382 smallest improvements in tinnitus-related handicap (statistically significant less than CBT, 383 HA, CBT+SC, CBT+ST, HA+SC), the additional beneficial effect of a treatment combination 384 appears to depend on how effective a single treatment already performs. For the single 385 treatment arm with ST, we observed a weak effect size of 0.24 (CI, -0.02 to 0.53) while 386 combinations of treatments including ST yielded medium to strong effect sizes: SC+ST 387 (Cohen's d = 0.71, CI, 0.46 to 1.02), HA+ST (Cohen's d = 0.78, CI, 0.43 to 1.37), and 388 CBT+ST (Cohen's d = 0.80. CI, 0.55 to 1.12), which is driven by the combination treatments 389 of higher efficacy.

390 The weak clinical efficacy of sound treatment alone is in line with previous work where 391 sound treatment was used as an active comparator.³⁷ This trial shows that combining a

392 treatment of weak clinical efficacy with a treatment of stronger clinical efficacy 393 counterbalanced the weak effect and provokes a clinical improvement comparable to the 394 stronger effect. On the other hand, if a single treatment is already effective, a combination 395 might not result in a synergistic effect.

396 Previous investigations evaluated combination treatments for tinnitus as well.⁹⁻¹¹ For instance 397 it was demonstrated that Tinnitus Retraining Therapy,¹² which combines a specific acoustic 398 therapy with directive counselling, reduced tinnitus symptoms more effectively than 399 counselling alone.⁹

However, this is the first systematic trial to investigate CBT, HA, ST, and SC within the scope of one investigation. With the present trial, we can directly put into perspective the effect size of CBT as the most established treatment in tinnitus,^{7,8,31} with HA, ST, and SC (ST and SC provided with mobile applications) as well as their combinations as treatment options for tinnitus. The combination of HA+SC, which provided the strongest effect size in our trial, has not been investigated so far, and data about the clinical efficacy in tinnitus are not yet available.^{38,39}

For the interpretation of the results, it should be considered that we worked with a selected set of four tinnitus treatments and combinations of two treatment types. Thus, it remains unknown, whether the combination of other treatment sets or combinations of three or more treatment types would lead to additional treatment benefits. The duration of treatment was 12 weeks in all treatment arms. Meaningful clinical improvements were observed in most treatment arms after 6 weeks and improved further towards the final assessment after 12 weeks and remained during the follow-up period.

Despite the usage of interventions allowing for a high level of patient flexibility (SC and ST via mobile applications, HA), treatment compliance/adherence was low (see **Table S35**) and drop-out rates were high in our trial (PP sample of 185 patients). With the application of two treatments in combination, the chances that one or even both treatments are not conducted as

418 intended are increasing. Further, high drop-out rates are a well-known issue in mobile health 419 interventions.⁴⁰ Another reason could be that patients were randomized to treatments and did 420 not receive the treatment they desired. Under ideal treatment compliance/adherence (PP 421 analysis), we observed no overall superiority of combination treatments.

422 A potential explanation for this incongruency between ITT and PP analysis might be that 423 under perfect conditions (PP), a single treatment which is conducted properly is already 424 effective on its own and thus there is no clear additional beneficial effect of a combination 425 treatment. However, if one or two treatments are not properly conducted (ITT), as it is most 426 probably the case in the everyday clinical treatment of tinnitus, a combination of treatments 427 provides an additional benefit. Our results indicate that there is a high need for further 428 research to better understand the clinical effects of combination treatment; to get more 429 profound insights behind the reasons for low treatment adherence; and in approaches to 430 increase treatment adherence in daily clinical practice, such as the implementation of 431 behavioral change techniques or more extensive patient education.

432 A placebo group was not included in this trial, as the answer to the main question 433 (comparison of single and combined treatment) did not require a placebo arm. Nevertheless, a 434 placebo group may have been helpful as an anchor for comparison with the ten treatment 435 arms. However, our results of CBT as single treatment correspond very well to meta-analytic data of its $efficacy^{31}$ and thus provide an anchor for a well-established evidence based 436 437 treatment approach. Further, our data demonstrates low efficacy of ST as a single treatment, supporting its use as an active control condition in randomised controlled trials.⁴¹ Thus, the 438 439 two treatment arms CBT and ST can be considered as reliable reference anchors for the 440 interpretation of the results of the other 8 investigated treatment arms.

Even though in 18% of all participants data of the primary outcome was missing, the
sensitivity analysis (no imputation of THI) came to a similar finding regarding our primary
objective.

Λ	Λ	Λ
T	т	T

In this trial involving adults with chronic tinnitus, we found that 12 weeks of treatment with CBT, HAs, SC, or ST applied as single or in combinations of two treatments led to an amelioration in tinnitus-related handicap. There was no unambiguous synergistic effect of treatment combination, rather a compensatory effect, where a more effective treatment offsets the clinical effects of a less effective treatment. In clinical situations where it is unclear which treatment will benefit the patient, a combination of treatments might help to increase the chances of treatment success.

452

453 **Contributions**

454 Stefan Schoisswohl (SSch) contributed to conceptualisation, investigation, formal analysis, 455 methodology, project administration, supervision, visualisation, and writing – original draft; 456 Winfried Schlee (WS) contributed to conceptualisation, funding acquisition, formal analysis, 457 methodology, project administration, supervision, visualisation, and writing – original draft; 458 Berthold Langguth (BL) contributed to conceptualisation, funding acquisition, methodology, 459 supervision, and writing – review & editing; Laura Basso (LB) and Milena Engelke (ME) 460 contributed to data curation, formal analysis, methodology, visualisation, and writing -461 original draft; Rüdiger Pryss (RP) contributed to funding acquisition, investigation, 462 methodology, software, and writing - review & editing; Birgit Mazurek (BM), Jose Antonio 463 Lopez-Escamez (JALE), Dimitrios Kikidis (DK), and Rilana Cima (RC) contributed to 464 conceptualisation, funding acquisition, methodology, and writing – review & editing; Myra 465 Spiliopoulou (MSp) contributed to funding acquisition, data curation, formal analysis, and 466 writing - review & editing; Susanne Staudinger (SStau) contributed to conceptualisation, 467 project administration, investigation, and writing – review & editing; Carsten Vogel (CV) 468 contributed to investigation, methodology, software, and writing – review & editing; Jorge 469 Simoes (JS), Uli Niemann (UN), Clara Puga (CP), Miro Schleicher (MSchl), Carlotta M.

470 Jarach (CMJ), Hafez Kader (HK), and Vishnu Unnikrishnan (VU) contributed to data 471 curation, formal analysis, methodology, and writing – review & editing; Benjamin Boecking 472 (BB) and Martin Schecklmann (MSche) contributed to conceptualisation, methodology, 473 investigation, and writing – review & editing; Christopher R. Cederroth (CRC) contributed to 474 funding acquisition, resources, and writing – review & editing; Steven C. Marcrum (SCM) 475 contributed to conceptualisation, investigation, and writing - review & editing; Patrick Neff 476 (PN) contributed to conceptualisation, methodology, and writing – review & editing; 477 Johannes Schobel (JS) contributed to investigation, software, and writing – review & editing; 478 Alberto Bernal-Robledano (ABR), Marta Martinez-Martinez (MMM), Nicolas Muller-479 Locatelli (NML), Patricia Perez-Carpena (PPC), Paula Robles-Bolivar (PRB), Matthias Rose 480 (MR), Tabea Schiele (TS), Sam Denys (SD), Alba Escalera-Balsera (AEB), Alvaro Gallego-481 Martinez (AGM), Leyre Hidalgo-Lopez (LHL), Nikos Markatos (NM), Juan Martin-Lagos 482 (JML), Sabine Stark (SSta), Alexandra Stege (AS), Evgenia Vassou (EV), Nicolas Verhaert 483 (NV), and Zoi Zachou (ZZ) contributed to investigation and writing – review & editing; Jan 484 Bulla (JB) and Beat Toedtli (BT) contributed to formal analysis, validation, and writing – 485 review & editing; Silvano Gallus (SG) contributed to funding acquisition and writing – 486 review & editing; Michael Koller (MK), Hazel Goedhart (HG) and Holger Crump (HC) 487 contributed to conceptualisation and writing – review & editing; and Alessandra Lugo (AL) 488 and Ilias Trochidis (IT) contributed to writing – review & editing. 489 All authors had full access to all the data in the study and had final responsibility for the

decision to submit for publication. SSch, WS, LB, and ME have directly accessed and verifiedthe underlying data reported in the manuscript.

492

493 Funding

494 This clinical trial received funding from the European Union's Horizon 2020 Research and

495 Innovation Program (grant agreement number: 848261). The funders had no influence on trial

design and had no role in the collection, analysis, interpretation of the data, preparation of themanuscript or in the decision to submit the manuscript for publication.

498

499 **Competing interests**

500 SSch received funding outside the present study from dtec.bw - Digitalization and 501 Technology Research Center of the Bundeswehr (MEXT project). dtec.bw is funded by the 502 European Union - NextGenerationEU. ME received research funding outside the present 503 study from the Rainwater Charitable Foundation and the Sonova Holding AG. BL received 504 consulting fees outside the present study from Schwabe Pharma AG, Neuromod, Sea Pharma, 505 and Rovi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript 506 writing or educational events outside the present study from Schwabe and Neuromod; 507 payment for expert testimony outside the present study from the Bavarian State; has an unpaid 508 leadership or fiduciary role outside the present study in the German Society for Brain 509 Stimulation in Psychiatry and the Tinnitus Research Initiative; owns stock or stock options 510 form Sea Pharma; and received equipment outside the present study from Neurocare and 511 Daymed. BM received support for attending meetings and/ or travel outside the present study 512 from the Charité – Universitätsmedizin Berlin. JALE received support for attending meetings 513 and conferences outside the present study from the University of Sydney. RC received 514 support for attending meetings and conferences outside the present study from the KU Leuven 515 University, Faculty of Psychology and Educational Sciences, Health Psychology, Belgium 516 and Adelante Center of Expertise in Rehabilitation and Audiology, The Netherlands, AEB 517 received research funding outside the present study from ibs.Granada/Fundación para la 518 Investigación Biosanitaria de Andalucía Oriental (FIBAO), European Molecular Biology 519 Organisation (EMBO) and Centro de Investigación Biomédica en Red Enfermedades Raras 520 (CIBERER). AGM received research funding outside the present study from the CECEU 521 2020, Andalusian Government of Spain (grant number: DOC_01677), and support for

522 attending meetings and/ or travel from the Andalusian Health Department (Grant number: PI-523 0266-2021 – GEN4PHEN). PPC received research funding outside the present study from the 524 Consejería de Salud y Familias, Junta de Andalucía. 2020, Contrato Posdoctorales 525 Especialistas (RH-0150-2020), and the Instituto de Salud Carlos III., Bases neurofisiológicas 526 y perfil de seguridad de la terapia sonora en pacientes con acúfeno crónico severo 527 (PI22/01838). RP is a stakeholder of the Lenox uG. The Lenox uG also holds shares of the 528 HealthStudyClub GmbH. MSp received payment or honoraria for lectures, presentations, 529 speaker bureaus, manuscript writing or educational events outside the present study from 530 VAIA (Vlaamse AI Academie: https://www.vaia.be/en/), which is a collaboration between all 531 the universities and universities for applied sciences and arts in Flanders; payment effected by 532 KU Leuven. NV received research funding outside the present study from the Flanders 533 Research Foundation and VLAIO - KU Leuven, and has a planned patent with KU Leuven. 534 WS is a stakeholder of the Lenox uG. Lenox uG also holds shares of the HealthStudyClub 535 GmbH; received consulting fees outside the present study from Pansatori GmbH and Pohl-536 Boskamp GmbH & Co. KG; received payment or honoraria for lectures, presentations, 537 speaker bureaus, manuscript writing or educational events outside the present study from 538 Schwabe Pharma AG and Medical Tribune; has a patent planned, issued or pending 539 (US20120046713A1).

540

541 Ethical approval

542 The study was approved by local ethics committees of Granada, Athens, Leuven, Regensburg543 and Berlin (combined ethical approval for German sites).

544

545 Data availability

- 546 De-identified data generated from this trial will initially be available only on request for
- 547 researchers to reproduce results, later publicly via ZENODO. Current data availability will be
- 548 reported on the UNITI website (https://uniti.tinnitusresearch.net/).
- 549

550

551 Acknowledgments

552 We would like to thank all patients who participated in this trial, without whom this research

553 would not have been possible. We would like to further thank the whole consortium of the

554 UNITI-project for their feedback and support. Moreover, we would like to thank Simon

555 Grund for his support regarding the mitml R package.

556

557 **References**

- 1. De Ridder, D. *et al.* Tinnitus and tinnitus disorder: Theoretical and operational definitions
- (an international multidisciplinary proposal). *Prog. Brain Res.* **260**, 1–25 (2021).
- Jarach, C. M. *et al.* Global Prevalence and Incidence of Tinnitus: A Systematic Review
 and Meta-analysis. *JAMA Neurol.* **79**, 888–900 (2022).
- 562 3. Baguley, D., McFerran, D. & Hall, D. Tinnitus. *The Lancet* **382**, 1600–1607 (2013).
- 563 4. Roberts, L. E. *et al.* Ringing Ears: The Neuroscience of Tinnitus. *J. Neurosci.* 30, 14972–
 564 14979 (2010).
- 565 5. Vanneste, S. & De Ridder, D. The auditory and non-auditory brain areas involved in
 566 tinnitus. An emergent property of multiple parallel overlapping subnetworks. *Front. Syst.*
- 567 *Neurosci.* **6**, 31 (2012).
- 568 6. Sanchez, T. G., Valim, C. C. A. & Schlee, W. Long-lasting total remission of tinnitus: A
- 569 systematic collection of cases. *Prog. Brain Res.* **260**, 269–282 (2021).

- 570 7. Mazurek, B. *et al.* S3 Guideline: Chronic Tinnitus: German Society for
 571 Otorhinolaryngology, Head and Neck Surgery e. V. (DGHNO-KHC). *HNO* 70, 795–827
- 572 (2022).
- 573 8. Cima, R. F. F. *et al.* A multidisciplinary European guideline for tinnitus: diagnostics,
 574 assessment, and treatment. *HNO* (2019) doi:10.1007/s00106-019-0633-7.
- 575 9. Bauer, C. A., Berry, J. L. & Brozoski, T. J. The effect of tinnitus retraining therapy on
- 576 chronic tinnitus: A controlled trial: A Controlled Trial of Tinnitus Retraining Therapy.
- 577 Laryngoscope Investig. Otolaryngol. 2, 166–177 (2017).
- 578 10. Cima, R. F. et al. Specialised treatment based on cognitive behaviour therapy versus usual
- 579 care for tinnitus: a randomised controlled trial. *The Lancet* **379**, 1951–1959 (2012).
- 580 11. Henry, J. A. et al. Tinnitus Management: Randomized Controlled Trial Comparing
- 581 Extended-Wear Hearing Aids, Conventional Hearing Aids, and Combination Instruments.
- 582 J. Am. Acad. Audiol. 28, 546–561 (2017).
- 583 12. Jastreboff, P. J. 25 Years of tinnitus retraining therapy. *HNO* **63**, 307–311 (2015).
- 584 13. Tunkel, D. E. et al. Clinical practice guideline: tinnitus executive summary. Otolaryngol.-
- 585 -Head Neck Surg. Off. J. Am. Acad. Otolaryngol.-Head Neck Surg. 151, 533–541 (2014).
- 586 14. Kikidis, D. et al. Methodological Aspects of Randomized Controlled Trials for Tinnitus:
- 587 A Systematic Review and How a Decision Support System Could Overcome Barriers. J.
 588 *Clin. Med.* 10, 1737 (2021).
- 589 15. Schlee, W. *et al.* Towards a unification of treatments and interventions for tinnitus
 590 patients: The EU research and innovation action UNITI. *Prog. Brain Res.* 260, 441–451
 591 (2021).
- 592 16. Schoisswohl, S. *et al.* Unification of Treatments and Interventions for Tinnitus Patients
 593 (UNITI): a study protocol for a multi-center randomized clinical trial. *Trials* 22, 875
 594 (2021).

- 595 17. Simoes, J. P. et al. The statistical analysis plan for the unification of treatments and
- interventions for tinnitus patients randomized clinical trial (UNITI-RCT). *Trials* 24, 472
 (2023).
- 598 18. Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: Updated
- 599 guidelines for reporting parallel group randomised trials. J. Pharmacol. Pharmacother. 1,
- 600 100–107 (2010).
- 19. Newman, C. W., Jacobson, G. P. & Spitzer, J. B. Development of the Tinnitus Handicap
 Inventory. *Arch. Otolaryngol. Head Neck Surg.* 122, 143–148 (1996).
- 20. Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening
 tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* 53, 695–699 (2005).
- 605 21. Cima, R. F. F. Bothersome tinnitus □: Cognitive behavioral perspectives. *HNO* 66, 369–
 606 374 (2018).
- 607 22. Keidser, G., Dillon, H., Flax, M., Ching, T. & Brewer, S. The NAL-NL2 Prescription
 608 Procedure. *Audiol. Res.* 1, (2011).
- 609 23. Vogel, C., Schobel, J., Schlee, W., Engelke, M. & Pryss, R. UNITI Mobile-EMI-Apps for
- 610 a Large-Scale European Study on Tinnitus. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc.
- 611 *IEEE Eng. Med. Biol. Soc. Annu. Int. Conf.* **2021**, 2358–2362 (2021).
- 612 24. Genitsaridi, E. et al. Standardised profiling for tinnitus research: The European School for
- 613 Interdisciplinary Tinnitus Research Screening Questionnaire (ESIT-SQ). *Hear. Res.* **377**,
- 614 353–359 (2019).
- 615 25. Meikle, M. *et al.* The Tinnitus Functional Index: Development of a New Clinical Measure
- 616 for Chronic, Intrusive Tinnitus. *Ear Hear.* **33**, 153–76 (2011).
- 617 26. Hiller, W. & Goebel, G. Rapid assessment of tinnitus-related psychological distress using
 618 the Mini-TQ. *Int. J. Audiol.* 43, 600–604 (2004).
- 619 27. Kroenke, K. & Spitzer, R. L. The PHQ-9: A New Depression Diagnostic and Severity
- 620 Measure. *Psychiatr. Ann.* **32**, 509–515 (2002).

- 621 28. Harper, A., Power, M. & WHOQOL Group, X. Development of the World Health
- 622 Organization WHOQOL-Bref quality of life assessment. *Psychol. Med.* 551–558 (1998).
- 623 29. Landgrebe, M. et al. The Tinnitus Research Initiative (TRI) database: A new approach for
- delineation of tinnitus subtypes and generation of predictors for treatment outcome. BMC
- 625 *Med. Inform. Decis. Mak.* **10**, (2010).
- 626 30. Adamchic, I. *et al.* Linking the Tinnitus Questionnaire and the subjective Clinical Global
- 627 Impression: Which differences are clinically important? *Health Qual. Life Outcomes* 10,
 628 79 (2012).
- 629 31. Fuller, T. *et al.* Cognitive behavioural therapy for tinnitus. *Cochrane Database Syst. Rev.*630 1, CD012614 (2020).
- 32. Quartagno, M., Grund, S. & Carpenter, J. jomo: A Flexible Package for Two-level Joint
 Modelling Multiple Imputation. *R J.* 11, 205–228 (2019).
- 633 33. Grund, S., Robitzsch, A. & Luedtke, O. mitml: Tools for Multiple Imputation in
 634 Multilevel Modeling. (2023).
- 635 34. Simões, J. et al. The Statistical Analysis Plan for the Unification of Treatments and
- 636 Interventions for Tinnitus Patients Randomized Clinical Trial (UNITI-RCT). (2022).
- 637 doi:10.21203/rs.3.rs-2123725/v1.
- 638 35. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models
 639 Using Ime4. J. Stat. Softw. 67, (2015).
- 640 36. Lenth, R. V. *et al.* emmeans: Estimated Marginal Means, aka Least-Squares Means.
 641 (2023).
- 642 37. Searchfield, G. D. & Sanders, P. J. A randomized single-blind controlled trial of a
 643 prototype digital polytherapeutic for tinnitus. *Front. Neurol.* 13, (2022).
- 644 38. Kikidis, D., Vassou, E., Markatos, N., Schlee, W. & Iliadou, E. Hearing Aid Fitting in
- 645 Tinnitus: A Scoping Review of Methodological Aspects and Effect on Tinnitus Distress
- 646 and Perception. J. Clin. Med. 10, 2896 (2021).

- 647 39. Sereda, M., Xia, J., El Refaie, A., Hall, D. A. & Hoare, D. J. Sound therapy (using
- 648 amplification devices and/or sound generators) for tinnitus. *Cochrane Database Syst. Rev.*
- 649 **12**, CD013094 (2018).
- 40. Meyerowitz-Katz, G. et al. Rates of Attrition and Dropout in App-Based Interventions for
- 651 Chronic Disease: Systematic Review and Meta-Analysis. J. Med. Internet Res. 22, e20283
- 652 (2020).
- 41. Conlon, B. et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in
- a large randomized trial. *Sci. Rep.* **12**, 10845 (2022).